BioMarin Pharmaceutical (NASDAQ: BMRN)
Key Data Points
BioMarin Pharmaceutical Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
BioMarin Pharmaceutical Company Info
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
News & Analysis
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
BioMarin: EPS Surges Past Expectations
BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.
BioMarin Reports 28% Jump in Revenue
The midcap biotech delivered solid Q3 results, driven by strong demand for rare genetic disorder therapies.
BioMarin: Q2 Revenue Soars 20%
BioMarin Pharmaceutical reported robust Q2 2024 financial results, driven by strong revenue growth and key product success.
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
Investors were expecting better top-line numbers from the company's earnings report.
Why BioMarin Pharmaceutical Tumbled on Thursday
While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.
Why BioMarin Pharmaceutical Stock Jumped by 10.3% on Friday
The rare-disease specialist might now have a true franchise-level drug following the approval of Voxzogo.
2 Upcoming FDA Approval Decisions That Investors Should Really Watch
The FDA is scheduled to announce these two key approval decisions in late November.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.